U.S. Water Utilities Stock News

Oruka Therapeutics (ORKA) drew fresh investor attention after reporting encouraging interim Phase 1 data for ORKA-002, highlighting a long half-life and sustained IL-17 inhibition that could support less frequent dosing in psoriasis and hidradenitis suppurativa. See our latest analysis for Oruka Therapeutics. The positive ORKA-002 readout and recent conference presence appear to have kept interest high, with a 1-day share price return of 2.77% and year to date share price return of 18.15%...

The Goldman Sachs Group, Inc.'s ( NYSE:GS ) dividend will be increasing from last year's payment of the same period to...

Key Insights Given the large stake in the stock by institutions, Zhihu's stock price might be vulnerable to their...

Key Insights Aptera Motors' significant insider ownership suggests inherent interests in company's expansion A total of...

GoodRx Holdings (NASDAQ:GDRX) has had a rough three months with its share price down 31%. However, the company's...

The board of Carriage Services, Inc. ( NYSE:CSV ) has announced that it will pay a dividend on the 2nd of March, with...

Key Insights Significantly high institutional ownership implies Cytek Biosciences' stock price is sensitive to their...

With a median price-to-sales (or "P/S") ratio of close to 1.3x in the Commercial Services industry in the United...

The board of KeyCorp ( NYSE:KEY ) has announced that it will pay a dividend on the 13th of March, with investors...

We feel now is a pretty good time to analyse Sangamo Therapeutics, Inc.'s ( NASDAQ:SGMO ) business as it appears the...

The board of AGCO Corporation ( NYSE:AGCO ) has announced that it will pay a dividend on the 16th of March, with...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Northwest Natural Holding Company's ( NYSE:NWN ) investors are due to receive a payment of $0.4925 per share on 13th of...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Autohome (ATHM) is back in focus after JPMorgan Chase & Co. cut its rating from overweight to neutral and reduced its outlook, just as the company announced a special dividend for shareholders. See our latest analysis for Autohome. At a share price of $23.09, Autohome’s recent moves, including crossing below its 200 day moving average and the JPMorgan downgrade, sit against a year to date share price return of 1.81% and a 1 year total shareholder return decline of 10.20%. This suggests near...

Skyward Specialty Insurance Group (SKWD) has expanded its E&S Property offering by adding Excess coverage. This move is aimed at supporting layered programs for technically complex, non catastrophe property risks and aligns with its "Rule Our Niche" focus. See our latest analysis for Skyward Specialty Insurance Group. Recent moves such as the new Excess E&S Property coverage and the term loan facility to support an acquisition come at a time when the 1 month share price return is a 9.09%...

Earlier in January 2026, Essent Group Ltd. announced a new US$500 million share repurchase authorization running through the end of 2027, with its Chairman and CEO underscoring the company’s strong capital position and continued discipline in mortgage insurance underwriting and risk management. This combination of ongoing buybacks and steady mortgage insurance operations highlights how Essent is using its capital strength to reinforce shareholder-focused capital allocation and long-term...

ASP Isotopes Inc. recently completed its acquisition of Renergen Limited, appointing Renergen CEO Stefano Marani as President, Electronics and Space, and COO Nick Mitchell as Co-Chief Operating Officer, while multiple law firms began investigating potential fiduciary duty breaches and securities issues tied to allegations about the company’s nuclear fuel technology disclosures. This combination of integration of helium and natural gas operations with ASP Isotopes’ enrichment technology and...

Guidance highlights for IMCIVREE driven revenue Rhythm Pharmaceuticals (RYTM) recently issued preliminary 2025 guidance that puts IMCIVREE at the center of the story, with management flagging sharp year over year gains in both quarterly and full year net product revenue. The company expects IMCIVREE net product revenue of about US$57 million for the fourth quarter of 2025, based on unaudited figures, which it says is an 11% sequential increase versus the third quarter. For the full year 2025,...

Earlier this month, UBS reported that Universal Health Services’ management expects no material impact from New York’s new Medicaid restrictions and the company extended CEO Marc D. Miller’s contract through 2029 with an updated base salary and performance-based bonus structure. This combination of limited exposure to a policy headwind affecting peers and clear leadership continuity offers investors additional context on UHS’s operating risk profile and governance stability. Next, we’ll...

NovaBay Pharmaceuticals (NBY) has reshaped its story with a private placement of pre funded warrants totaling about US$134 million, largely paid in digital assets, and a pivot toward a SKY token focused treasury model. See our latest analysis for NovaBay Pharmaceuticals. The financing news comes after a very sharp 30 day share price return of 178.68% and a very large 1 year total shareholder return, although the 3 and 5 year total shareholder returns are still deeply negative, so long term...

Annexon, Inc. recently submitted a Marketing Authorization Application to the European Medicines Agency for tanruprubart, a first-in-class antibody targeting complement-driven inflammation in Guillain-Barre syndrome, supported by randomized Phase 3 data and ongoing FORWARD study observations. This move underscores Annexon’s focus on severe neuroinflammatory diseases with limited treatment options, aiming to position tanruprubart as a potential new standard of care in GBS. We’ll now examine...

PENN Entertainment, Inc. recently implemented a new corporate organizational structure that realigns its Interactive division around Canadian digital assets and its Hollywood iCasino product in the US, eliminates two senior executive roles, and consolidates enterprise technology and digital operations under Chief Technology Officer and Head of Interactive Aaron LaBerge. This reshaping of leadership and responsibilities is intended to more tightly connect PENN’s retail casinos with its...

Ryan Specialty Holdings (RYAN) has come into focus after several analysts, including Cantor Fitzgerald and Barclays, trimmed their expectations for the stock, citing softer commercial and reinsurance markets and potential near term fundamental pressure. See our latest analysis for Ryan Specialty Holdings. Ryan Specialty Holdings’ recent move to a US$51.48 share price comes after analyst commentary on softer commercial and reinsurance conditions. A 1-year total shareholder return decline of...